ClinicalTrials.gg
CompletedNCT00904202Updated Jan 2, 2024

A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions

A Phase 4 interventional study of Placebo Capsules + Placebo Patch and Placebo capsules + Lidoderm® in Postherpetic Neuralgia, Diabetic Neuropathy and Complex Regional Pain Syndrome, sponsored by Endo Pharmaceuticals. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-02.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies in Neuralgia, Postherpetic with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Neuralgia, Postherpetic · United States.

Enrollment
33rd of 56
62 · median 93
Started
2003
with 1 other
Phase 4
4 of 60
none open now
Registered
28th of 60
by date
Lead sponsor
2 of 60
Endo Pharmaceuticals

Among the 60 studies in Neuralgia, Postherpetic with a site in United States, this one is the 33rd largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2003, is one of 4 in phase 4, and was the 28th registered.

Neuralgia, Postherpetic

197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.

Browse Neuralgia, Postherpetic studies →

Open to participants now

4 of the 60 studies in Neuralgia, Postherpetic with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Neuralgia, Postherpetic with a site in United States, or all of them as a file.
02

Study summary

Patients with postherpetic neuralgia (PHN), diabetic neuropathy (DN), complex regional pain syndrome (CRPS), carpal tunnel syndrome, HIV neuropathy, idiopathic sensory neuropathy, or other peripheral neuropathy participated in a Phase IV clinical trial to assess the comparative efficacy and safety of Lidoderm monotherapy versus gabapentin monotherapy in treating a diverse group of peripheral neuropathic pain patients.

03

Conditions studied

  • Postherpetic Neuralgia
  • Diabetic Neuropathy
  • Complex Regional Pain Syndrome
  • Carpal Tunnel Syndrome
  • HIV Neuropathy
  • Idiopathic Sensory Neuropathy
  • Peripheral Neuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Had a diagnosis of PHN, DN, CRPS, carpal tunnel syndrome, neuropathy, idiopathic sensory neuropathy, or other peripheral neuropathy (upon mutual agreement of the sponsor and investigator)
  2. Patients with PHN must have had pain >3 months after rash healing
  3. Patients with DN must have had Type I or II diabetes and painful distal symmetric sensorimotor polyneuropathy with or without dynamic allodynia of the lower extremities
  4. Patients with CRPS must have met current IASP (International Association for the Study of Pain) diagnostic criteria
  5. Patients with carpal tunnel syndrome must have had a diagnosis by combination clinical neurological examination (e.g., Phalen's and Tinel's signs), electrodiagnostic testing, and daily painful symptoms of at least 3 months' duration
  6. Patients with HIV neuropathy must have had HIV, subjective symptoms of painful peripheral neuropathy, and daily painful symptoms of at least 3 months' duration
  7. Patients with idiopathic sensory neuropathy must have had pain of at least 3 months' duration
  8. Reached an average daily pain rating during the baseline week of pain ratings greater than 4 on the 0-to-10 numerical pain rating scale (Question 5 of the BPI)
  9. Had never received an analgesic regimen that contained lidocaine or gabapentin

Exclusion criteria

Exclusion Criteria:

  1. Had a neurological condition other than that associated with their pain diagnosis which, in the opinion of the investigator, would interfere with their ability to participate in the study
  2. Were taking a lidocaine-containing product that could not be discontinued while receiving lidocaine
  3. Were taking class 1 anti-arrhythmic drugs (e.g., mexiletine, tocainide)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
62 participants (actual)

Study arms

  • Placebo comparator
    placebo capsules + placebo patch

    Placebo to match lidocaine patch; up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing

    Drug: Placebo Capsules + Placebo Patch

  • Experimental
    placebo capsules + Lidoderm patch (Lidocaine Group)

    Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain AND Placebo capsules to match gabapentin for oral dosing

    Drug: Placebo capsules + Lidoderm®

  • Active comparator
    Gabapentin capsules 1800 mg/day + placebo patch

    Gabapentin 300 mg capsules for oral dosing at a dose of 1800 mg/day AND Placebo patch to match lidocaine patch; up to four patches applied topically daily (q24h) to the area of maximal peripheral pain

    Drug: Gabapentin + Placebo · Drug: Gabapentin 300 mg capsules 1800 mg/day + placebo patch

  • Other
    Gabapentin capsules 1800 mg/day + Lidoderm patch

    Gabapentin 1800 mg/day AND Lidoderm (lidocaine patch 5%), up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain

    Drug: Gabapentin + Lidoderm® · Drug: Gabapentin 1800 mg/day + Lidoderm patch

Interventions

  • DrugPlacebo Capsules + Placebo Patch

    Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).

    Also known as: Lidocaine patch 5%

  • DrugPlacebo capsules + Lidoderm®

    Drug page: Lidoderm

    Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).

    Also known as: Lidocaine patch 5%

  • DrugGabapentin + Placebo

    Drug page: Lidoderm

    Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).

    Also known as: Lidocaine patch 5%

  • DrugGabapentin + Lidoderm®

    Drug pages: Gabapentin · Lidoderm

    Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).

    Also known as: Lidocaine patch 5%

  • DrugGabapentin 300 mg capsules 1800 mg/day + placebo patch

    Gabapentin 300 mg capsules 1800 mg/day + placebo patch

  • DrugGabapentin 1800 mg/day + Lidoderm patch

    Drug page: Gabapentin

06

What researchers measure

Primary outcomes

  1. Average daily pain intensity (BPI Questions 3,4,5, and 6)

    Time frame: Visit - V2 (Day 0), V3 (Day 7), V4 (Day 14), V5 (Day 21), V6 (Day 28), V7/EOS (Day 35)

Secondary outcomes

  1. Pain Quality Assessment Scale (PQAS)

  2. Investigator and Patient Global Impression of Change

  3. Allodynia Testing

  4. QoL; Symptom Checklist, pain interference with QoL

  5. Patient Global Impression of Treatment Satisfaction, disability assessment, and Percent Pain Relief (BPI Question 8)

  6. Safety assessments include adverse events; dermal assessments/sensory testing, clinical laboratory tests, vital sign measurements and physical/neurological examination

07

Study locations

7 sites
  • Birmingham, Alabama, United States
  • Hueytown, Alabama, United States
  • Phoenix, Arizona, United States
  • Pembroke Pines, Florida, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Altoona, Pennsylvania, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003 and a primary completion of Jun 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2009
First posted
May 19, 2009
Start
Jan 2003
Primary completionActual
Jun 2003
Last update
Jan 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00904202
First posted
May 19, 2009
Start date
Jan 2003
Primary completion
Jun 2003
Last update
Jan 2, 2024

Study contacts

Sr Director
study director · Endo Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidoderm

Start the discussion